The blockade of immune checkpoints in cancer immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Control of Regulatory T Cell Development by the Transcription Factor <i>Foxp3</i>

Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187 · see citing works

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 3,960 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259 · see citing works

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,204 · see citing works

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

CD28/B7 SYSTEM OF T CELL COSTIMULATION

Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · see citing works

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · see citing works

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D. J., Usheva, A., Erat, A., Chen, J., Enjyoji, K., Linden, J. M., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,478 · see citing works

The B7 family revisited

Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · see citing works

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · see citing works

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · see citing works

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · see citing works

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,733 · see citing works

CTLA-4 is a second receptor for the B cell activation antigen B7.

Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · see citing works

Up on the tightrope: natural killer cell activation and inhibition

Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656 · see citing works

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works

Inhibitory B7-family molecules in the tumour microenvironment

Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works

Combining immunotherapy and targeted therapies in cancer treatment

Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,583 · see citing works

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 ⁺ T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Role of LAG-3 in Regulatory T Cells

Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325 · see citing works

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works

PD-1 and PD-1 ligands: from discovery to clinical application

Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · see citing works

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · see citing works

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293 · see citing works

Tissue expression of PD-L1 mediates peripheral T cell tolerance

Keir, M., Liang, S. C., Guleria, I., Latchman, Y., Qipo, A., Albacker, L., Koulmanda, M., Freeman, G., Sayegh, M., & Sharpe, A. (2006) · Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,264 · see citing works

Foxp3-dependent programme of regulatory T-cell differentiation

Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05543 · Cited by 1,127 · see citing works

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

Rosenwald, A., Wright, G. W., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haïoun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,095 · see citing works

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,074 · see citing works

Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3 . Science 2003. 299: 1057–1061

Hori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,067 · see citing works

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 977 · see citing works

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

LAG-3, a novel lymphocyte activation gene closely related to CD4.

Triebel, F., Jitsukawa, S., Baixerás, E., Roman‐Roman, S., Genevée, C., Viégas-Pèquignot, E., & Hercend, T. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1393 · Cited by 917 · see citing works

B70 antigen is a second ligand for CTLA-4 and CD28

Azuma, M., Ito, D., Yagita∥, H., Okumura, K., Phillips, J. H., Lanier, L. L., & Somoza, C. (1993) · Nature · doi:10.1038/366076a0 · Cited by 910 · see citing works

Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S., & Nadler, L. M. (1993) · Science · doi:10.1126/science.7694363 · Cited by 903 · see citing works

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · see citing works

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 897 · see citing works

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · see citing works

B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

Tseng, S.-Y., Otsuji, M., Gorski, K. S., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 867 · see citing works

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · see citing works

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · see citing works

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · see citing works

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works

An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J. P., Alaparthy, S., Berman, D., Jure‐Kunkel, M., Siemers, N. O., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 771 · see citing works

Enhancing SIV-specific immunity in vivo by PD-1 blockade

Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L. S., Silvestri, G., Freeman, G. J., et al. (2008) · Nature · doi:10.1038/nature07662 · Cited by 765 · see citing works

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

Fife, B. T., Pauken, K. E., Eagar, T. N., Kangas, T. O., Wu, J. Q., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759 · see citing works

T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

Linsley, P. S., Clark, E. A., & Ledbetter, J. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5031 · Cited by 755 · see citing works

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731 · see citing works

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

Rodrı́guez, P. C., & Ochoa, A. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00608.x · Cited by 722 · see citing works

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

Konishi, J. S., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka‐Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678 · see citing works

Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature.

Hill, J., Feuerer, M., Tash, K., Haxhinasto, S., Perez, J., Melamed, R., Mathis, D., & Benoist, C. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.010 · Cited by 671 · see citing works

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & TOKURA, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 668 · see citing works

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

Šedý, J. R., Gavrieli, M., Potter, K. G., Hurchla, M. A., Lindsley, R. C., Hildner, K. M., Scheu, S., Pfeffer, K., Ware, C. F., Murphy, T. L., et al. (2004) · Nature Immunology · doi:10.1038/ni1144 · Cited by 633 · see citing works

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works

Reversal of the TCR Stop Signal by CTLA-4

Schneider, H., Downey, J., Smith, A. M., Zinselmeyer, B. H., Rush, C. M., Brewer, J. M., Wei, B. K., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621 · see citing works

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 613 · see citing works

The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

Ghebeh, H., Mohammed, S. F., Al-Omair, A., Qattan, A. T., Lehé, C. L., Al-Qudaihi, G., Elkum, N. B., Alshabanah, M., Amer, S. M. B., Tulbah, A. M., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612 · see citing works

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · see citing works

Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses

Hou, D., Muller, A. J., Sharma, M. D., DuHadaway, J. B., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586 · see citing works

Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors

Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita∥, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 575 · see citing works

CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients

Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · cited 1× · see citing works

Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength

Egen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 534 · see citing works

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Grosso, J., Kelleher, C. C., Harris, T., Maris, C. H., Hipkiss, E. L., Marzo, A. D. D., Anders, R., Netto, G., Getnet, D., Bruno, T., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31184 · Cited by 531 · see citing works

Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation

Hathcock, K. S., László, G., Dickler, H. B., Bradshaw, J., Linsley, P. S., & Hodes, R. J. (1993) · Science · doi:10.1126/science.7694361 · Cited by 517 · see citing works

Improved Endpoints for Cancer Immunotherapy Trials

Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R. A., Anderson, A., Humphrey, R. W., Blumenstein, B. A., Old, L. J., & Wolchok, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 517 · see citing works

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells

Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J. M., Drake, C. G., & Powell, J. D. (2007) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 516 · see citing works

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 492 · see citing works

Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma

Ochoa, A. C., Zea, A. H., Hernandez, C., & Rodrı́guez, P. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2197 · Cited by 489 · see citing works

618: Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(18)34858-4 · Cited by 386 · see citing works

IL-18 Induces PD-1–Dependent Immunosuppression in Cancer

Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376 · see citing works

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1

Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372 · see citing works

Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection

Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A. B., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 366 · see citing works

Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses

Mellor, A. L., Keskin, D. B., Johnson, T. S., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348 · see citing works

LAG-3 in Cancer Immunotherapy

Goldberg, M. V., & Drake, C. G. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_114 · Cited by 337 · see citing works

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

Park, J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., Augustine, M. M., Yao, S., Tsushima, F., Narazaki, H., Anand, S., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265975 · Cited by 331 · see citing works

Integrated NY-ESO-1 antibody and CD8 + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Yuan, J. D., Adamow, M. J., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 329 · see citing works

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

Riley, J. L., Mao, M., Kobayashi, S., Biery, M. C., Burchard, J., Cavet, G., Gregson, B. P., June, C. H., & Linsley, P. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162359999 · Cited by 307 · see citing works

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H., Opelz, G., & Terness, P. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 305 · see citing works

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

Grosso, J. F., Goldberg, M. V., Getnet, D., Bruno, T. C., Yen, H., Pyle, K. J., Hipkiss, E. L., Vignali, D. A. A., Pardoll, D. M., & Drake, C. G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804211 · Cited by 272 · see citing works

Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250 · see citing works

Human prostate‐infiltrating CD8 + T lymphocytes are oligoclonal and PD‐1 +

Sfanos, K. S., Bruno, T. C., Meeker, A. K., Marzo, A. M. D., Isaacs, W. B., & Drake, C. G. (2009) · The Prostate · doi:10.1002/pros.21020 · Cited by 233 · see citing works

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

Paterson, A. M., Brown, K. E., Keir, M. E., Vanguri, V. K., Riella, L. V., Chandraker, A. K., Sayegh, M. H., Blazar, B. R., Freeman, G. J., & Sharpe, A. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003496 · Cited by 202 · see citing works

Missing self recognition and self tolerance of natural killer (NK) cells

Raulet, D. H. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.003 · Cited by 195 · see citing works

Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

Li, B., VanRoey, M. J., Wang, C., Chen, T.-H. T., Korman, A. J., & Jooss, K. U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1825 · Cited by 191 · see citing works

Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

Baitsch, L., Legat, A., Barba, L., Marraco, S. A. F., Rivals, J., Baumgaertner, P., Christiansen-Jucht, C., Bouzourène, H., Rimoldi, D., Pircher, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030852 · Cited by 184 · see citing works

Fine tuning the immune response through B7‐H3 and B7‐H4

Yi, K. H., & Chen, L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00768.x · Cited by 172 · see citing works

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 152 · see citing works

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

Waickman, A. T., Alme, A., Senaldi, L., Zarek, P. E., Horton, M. R., & Powell, J. D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1155-7 · Cited by 151 · see citing works

Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer

Qian, F., Villella, J., Wallace, P. K., Mhawech-Fauceglia, P. Y., Tario, J. D., Andrews, C., Matsuzaki, J., Valmori, D., Ayyoub, M., Frederick, P. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2106 · Cited by 147 · see citing works

Dual biological effects of the cytokines interleukin-10 and interferon-γ

Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138 · see citing works

Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells

Kim, J., Myers, A. C., Chen, L., Pardoll, D. M., Truong-Tran, Q. A., Lane, A. P., McDyer, J. F., Fortuno, L. V., & Schleimer, R. P. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0129oc · Cited by 137 · see citing works

Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab

Ribas, A. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.010 · Cited by 132 · see citing works

IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells

Lee, S., SEO, S., Kim, B. C., Kim, C. D., Lee, J. H., Kang, J., Maeng, P. J., & Lim, J. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.06.008 · Cited by 123 · see citing works

New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas

Fanoni, D., Tavecchio, S., Recalcati, S., Balice, Y., Venegoni, L., Fiorani, R., CROSTI, C., & Berti, E. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.022 · Cited by 115 · see citing works

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer

Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. C., & Yang, R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.030 · Cited by 102 · see citing works

Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression

Bąk, S., Alonso, A., Turk, M. J., & Berwin, B. L. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.266 · Cited by 95 · see citing works

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

Sznol, M., Powderly, J. D., Smith, D. C., Brahmer, J. R., Drake, C. G., McDermott, D. F., Lawrence, D. P., Wolchok, J. D., Topalian, S. L., & Lowy, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2506 · Cited by 85 · see citing works

Cutting Edge: CTLA-4 (CD152) Differentially Regulates Mitogen-Activated Protein Kinases (Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase) in CD4+ T Cells from Receptor/Ligand-Deficient Mice

Schneider, H., Mandelbrot, D. A., Greenwald, R. J., Ng, W., Lechler, R. I., Sharpe, A. H., & Rudd, C. E. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3475 · Cited by 75 · see citing works

The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival

He, C., Qiao, H., Jiang, H., & Sun, X. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/695834 · Cited by 70 · see citing works

Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice

Lasaro, M. O., Sazanovich, M., Giles‐Davis, W., Mrass, P., Bunte, R. M., Sewell, D. A., Hussain, S. F., Fu, Y., Weninger, W., Paterson, Y. Y. W., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.88 · Cited by 48 · see citing works

Arginase Activity is Inhibited by l -NAME, both In Vitro and In Vivo

Reisser, D., Onier-Cherix, N., & Jeannin, J. (2002) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/1475636021000006252 · Cited by 36 · see citing works

Cancer Immunology, Immunotherapy

(2013) · Cancer Immunology Immunotherapy · doi:10.1007/262.1432-0851 · Cited by 34 · see citing works

Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors

Mingari, M. C., Pietra, G., & Moretta, L. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.03.006 · Cited by 31 · see citing works

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

McDermott, D. F., Drake, C. G., Sznol, M., Sosman, J. A., Smith, D. C., Powderly, J. D., Feltquate, D., Kollia, G. D., Gupta, A. K., & Wigginton, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.7_suppl.331 · Cited by 29 · see citing works

Extending Missing-Self? Functional Interactions Between Lectin-like Nkrp1 Receptors on NK Cells with Lectin-like Ligands

Plougastel-Douglas, B., & Yokoyama, W. M. (2005) · Current topics in microbiology and immunology · doi:10.1007/3-540-27743-9_4 · Cited by 22 · see citing works

Corrigendum to “IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells” [J. Dermatol. Sci. 40 (2005) 95–103]

Lee, S.-K., Seo, S.-H., Kim, B.-S., Kim, C. D., Jeung-Hoon, L., Kang, J.-S., Maeng, P. J., & Lim, J.-S. (2006) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2006.04.005 · Cited by 8 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells

Li, T., Fan, J., Wang, B., Traugh, N. C., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,914 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741 · see citing works

Molecular and cellular insights into T cell exhaustion

Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · see citing works

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593 · see citing works

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Lung cancer: current therapies and new targeted treatments

Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L. L. C., & Paz-Ares, L. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,278 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., den Eynden, G. V., Baehner, F. L., Penault-Llorca, F. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,142 · see citing works

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works

The prognostic landscape of genes and infiltrating immune cells across human cancers

Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,097 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079 · see citing works

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,815 · see citing works

The PI3K Pathway in Human Disease

Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694 · see citing works

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683 · see citing works

Delivery technologies for cancer immunotherapy

Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,621 · see citing works

Triple-negative breast cancer molecular subtyping and treatment progress

Yin, L., Duan, J., Bian, X.-W., & Yu, S. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,473 · see citing works

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · see citing works

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434 · see citing works

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

Li, B., Severson, E. A., Pignon, J., Zhao, H., Li, T., Novak, J. S. S., Jiang, P., Shen, H., Aster, J. C., Rodig, S. J., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,419 · see citing works

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · see citing works

Single-cell reconstruction of the early maternal–fetal interface in humans

Vento-Tormo, R., Efremova, M., Botting, R. A., Turco, M. Y., Vento-Tormo, M., Meyer, K. B., Park, J.-E., Stephenson, E., Polański, K., Goncalves, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0698-6 · Cited by 2,358 · see citing works

Pyroptosis: Mechanisms and Diseases

Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

PD-L1 expression as a predictive biomarker in cancer immunotherapy

Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · see citing works

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Duma, N., Santana-Dávila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,218 · see citing works

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works

Roles of the immune system in cancer: From tumor initiation to metastatic progression

Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes &amp; Development · doi:10.1101/gad.314617.118 · Cited by 2,111 · see citing works

Development of therapeutic antibodies for the treatment of diseases

Lu, R., Hwang, Y., Liu, I.-J., Lee, C., Tsai, H.-Z., Li, H., & Wu, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,106 · see citing works

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Deng, L., Liang, H. L., Burnette, B., Beckett, M., Darga, T. E., Weichselbaum, R. R., & Fu, Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,101 · see citing works

Cancer immunotherapy via dendritic cells

Palucka, K., & Banchereau, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3258 · Cited by 2,060 · see citing works

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053 · see citing works

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022 · see citing works

The diverse functions of the PD1 inhibitory pathway

Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 1,980 · see citing works

Tumor microenvironment as a therapeutic target in cancer

Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,977 · see citing works

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · see citing works

Molecular therapies and precision medicine for hepatocellular carcinoma

Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,948 · see citing works

Non-small cell lung cancer: current treatment and future advances

Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944 · see citing works

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · see citing works

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Cortés, J., Cescon, D. W., Rugo, H. S., Nowecki, Z. I., Im, S., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,822 · see citing works

Nanotechnology for Multimodal Synergistic Cancer Therapy

Fan, W., Yung, B. C., Huang, P., & Chen, X. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,804 · see citing works

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · see citing works

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Alsaab, H. O., Sau, S., Alzhrani, R. M., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,715 · see citing works

Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer

Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · see citing works

Phenotype molding of stromal cells in the lung tumor microenvironment

Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., Pircher, A., Van den Eynde, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0096-5 · Cited by 1,648 · see citing works

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,600 · see citing works

Combining immunotherapy and targeted therapies in cancer treatment

Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,583 · see citing works

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · see citing works

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575 · see citing works

Organoid modeling of the tumor immune microenvironment

Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556 · see citing works

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,553 · see citing works

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy

Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520 · see citing works

Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses

Yang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., Peng, R., & Liu, Z. (2017) · Nature Communications · doi:10.1038/s41467-017-01050-0 · Cited by 1,491 · see citing works

Tumour-intrinsic resistance to immune checkpoint blockade

Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,491 · see citing works

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487 · see citing works

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works

Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration

Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · see citing works

Macrophages and Therapeutic Resistance in Cancer

Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · see citing works

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471 · see citing works

CD8+ T cell states in human cancer: insights from single-cell analysis

van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,439 · see citing works

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · see citing works

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,412 · see citing works

Role of tumor microenvironment in tumorigenesis

Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404 · see citing works

PD-L1 Expression in Triple-Negative Breast Cancer

Mittendorf, E. A., Philips, A. V., Meric‐Bernstam, F., Qiao, N., Wu, Y., Harrington, S. M., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akçakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,394 · see citing works

Mechanisms of resistance to immune checkpoint inhibitors

Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · see citing works

A review of cancer immunotherapy toxicity

Kennedy, L. B., & Salama, A. K. S. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,376 · see citing works

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works

Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Balar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P. D., Vuky, J., Powles, T. B., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,336 · see citing works

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,325 · see citing works

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310 · see citing works

Type I interferons in anticancer immunity

Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305 · see citing works

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · see citing works

Genomic spectra of biliary tract cancer

Nakamura, H. K., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,288 · see citing works

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works

Immune checkpoint blockade opens a new way to cancer immunotherapy

Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 118 · see citing works

Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints

Yogesh, K. S. (2012) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-262018

Anticorpos bloqueadores dos checkpoints imunes

Gonçalves, R. M. B. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Checkpoint blocking antibodies in cancer immunotherapy

Kyi, C., & Postow, M. A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.015 · Cited by 245 · see citing works